Sanofi's Consumer Business Starts 2017 With 'Reassuring' Momentum
This article was originally published in The Pink Sheet
Executive Summary
Sanofi consumer products head Alan Main says BI's brands will "lift Sanofi into leadership positions in attractive OTC categories, namely the vitamins and minerals supplements market, digestive products, cough and cold as well as pain medications."
You may also be interested in...
Xyzal Switch Extends Sanofi Into OTC 24-Hour Children's Antihistamine
FDA approval of Xyzal Allergy 24HR enables Sanofi to compete in the once-daily OTC pediatric antihistamine space in the US.
Sanofi CEO Sets Growth Target For Consumer Health Business
CEO Brandicourt looks to Alan Main to lead return to mid-single-digit growth for consumer brands.
Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation
Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.